Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction.
The bradycardic agent ivabradine has proved to be of benefit in experimental models with the end points of ischaemic myocardial blood flow and contractile function, infarct size, post-infarct remodelling and atherosclerosis. The benefits to ischaemic myocardial blood flow and contractile function are strictly heart rate dependent; those on infarct size are partly heart rate independent. The heart rate dependency of ivabradine's benefit for atherosclerotic vascular function is contradictory, and that on post-infarct remodelling is entirely unclear.
Heusch
G
G
Institute for Pathophysiology, University of Essen Medical School, Essen, Germany. gerd.heusch@uk-essen.de
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000503:physiopathology; D001552:Benzazepines / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D000077550:Ivabradine; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000503:physiopathology; D020257:Ventricular Remodeling / Q000187:drug effects
D001552:Benzazepines; D002316:Cardiotonic Agents; D000077550:Ivabradine